Could a gorilla virus help beat HIV? new vaccine trial launches

NCT ID NCT06617091

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: International AIDS Vaccine Initiative Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 1 trial is testing a new HIV vaccine called GRAdHIVNE1, made using a harmless gorilla virus to deliver HIV protein pieces. The study will enroll 120 healthy adults in southern Africa, some living with HIV and some without, to check safety and measure immune responses. Participants will receive either the vaccine or a placebo, and researchers will monitor for side effects and T-cell activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GRAdHIVNE1 vaccine (a gorilla adenovirus vector vaccine)
What this could lead to: If successful, this could pave the way for a preventive HIV vaccine that works in both HIV-negative and HIV-positive people.
What could go wrong: This is an early Phase 1 trial with only 120 participants, so it is primarily testing safety and immune response, not effectiveness. The vaccine may not produce strong or lasting immunity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV

Contacts and locations

Locations

AHRI
RECRUITING

Mtubatuba, KwaZulu-Natal, South Africa
DTHF
RECRUITING

Cape Town, Western Cape, South Africa
Mutala
RECRUITING

Harare, Harare, Zimbabwe

More trials for these conditions

Other studies related to the condition(s) this trial covers.